vs
BYLINE BANCORP, INC.（BY）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是BYLINE BANCORP, INC.的1.8倍（$207.3M vs $112.4M），BYLINE BANCORP, INC.净利率更高（33.4% vs -62.0%，领先95.5%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 9.0%），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 6.4%）
Byline Bank是总部位于美国伊利诺伊州芝加哥的银行，为银行控股公司Byline Bancorp, Inc.的核心子公司，同时是全美SBA 7(a)贷款项目的第四大放贷机构，为客户提供专业的银行及融资相关服务。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
BY vs RARE — 直观对比
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $112.4M | $207.3M |
| 净利润 | $37.6M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | — | -54.7% |
| 净利率 | 33.4% | -62.0% |
| 营收同比 | 9.0% | 25.9% |
| 净利润同比 | 33.0% | 3.5% |
| 每股收益（稀释后） | $0.83 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | $112.4M | — | ||
| Q4 25 | $117.0M | $207.3M | ||
| Q3 25 | $115.7M | $159.9M | ||
| Q2 25 | $110.5M | $166.5M | ||
| Q1 25 | $103.1M | $139.3M | ||
| Q4 24 | $104.7M | $164.6M | ||
| Q3 24 | $101.8M | $139.5M | ||
| Q2 24 | $99.4M | $147.0M |
| Q1 26 | $37.6M | — | ||
| Q4 25 | $34.5M | $-128.6M | ||
| Q3 25 | $37.2M | $-180.4M | ||
| Q2 25 | $30.1M | $-115.0M | ||
| Q1 25 | $28.2M | $-151.1M | ||
| Q4 24 | $30.3M | $-133.2M | ||
| Q3 24 | $30.3M | $-133.5M | ||
| Q2 24 | $29.7M | $-131.6M |
| Q1 26 | — | — | ||
| Q4 25 | 40.1% | -54.7% | ||
| Q3 25 | 43.1% | -106.9% | ||
| Q2 25 | 35.2% | -64.8% | ||
| Q1 25 | 36.4% | -102.6% | ||
| Q4 24 | 38.6% | -74.3% | ||
| Q3 24 | 39.3% | -94.6% | ||
| Q2 24 | 40.4% | -79.1% |
| Q1 26 | 33.4% | — | ||
| Q4 25 | 34.1% | -62.0% | ||
| Q3 25 | 32.1% | -112.8% | ||
| Q2 25 | 27.2% | -69.0% | ||
| Q1 25 | 27.4% | -108.5% | ||
| Q4 24 | 34.3% | -80.9% | ||
| Q3 24 | 29.8% | -95.7% | ||
| Q2 24 | 29.9% | -89.5% |
| Q1 26 | $0.83 | — | ||
| Q4 25 | $0.77 | $-1.28 | ||
| Q3 25 | $0.82 | $-1.81 | ||
| Q2 25 | $0.66 | $-1.17 | ||
| Q1 25 | $0.64 | $-1.57 | ||
| Q4 24 | $0.68 | $-1.34 | ||
| Q3 24 | $0.69 | $-1.40 | ||
| Q2 24 | $0.68 | $-1.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $198.4M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.3B | $-80.0M |
| 总资产 | $9.9B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q1 26 | $198.4M | — | ||
| Q4 25 | $149.1M | $421.0M | ||
| Q3 25 | $259.0M | $202.5M | ||
| Q2 25 | $218.3M | $176.3M | ||
| Q1 25 | $421.3M | $127.1M | ||
| Q4 24 | $563.1M | $174.0M | ||
| Q3 24 | $452.6M | $150.6M | ||
| Q2 24 | $730.5M | $480.7M |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $-80.0M | ||
| Q3 25 | $1.2B | $9.2M | ||
| Q2 25 | $1.2B | $151.3M | ||
| Q1 25 | $1.1B | $144.2M | ||
| Q4 24 | $1.1B | $255.0M | ||
| Q3 24 | $1.1B | $346.8M | ||
| Q2 24 | $1.0B | $432.4M |
| Q1 26 | $9.9B | — | ||
| Q4 25 | $9.7B | $1.5B | ||
| Q3 25 | $9.8B | $1.2B | ||
| Q2 25 | $9.7B | $1.3B | ||
| Q1 25 | $9.6B | $1.3B | ||
| Q4 24 | $9.5B | $1.5B | ||
| Q3 24 | $9.4B | $1.5B | ||
| Q2 24 | $9.6B | $1.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
| Q1 26 | — | — | ||
| Q4 25 | $140.3M | $-99.8M | ||
| Q3 25 | $38.3M | $-91.4M | ||
| Q2 25 | $16.3M | $-108.3M | ||
| Q1 25 | $27.1M | $-166.5M | ||
| Q4 24 | $175.2M | $-79.3M | ||
| Q3 24 | $19.8M | $-67.0M | ||
| Q2 24 | $40.1M | $-77.0M |
| Q1 26 | — | — | ||
| Q4 25 | $136.3M | $-100.8M | ||
| Q3 25 | $38.0M | $-92.7M | ||
| Q2 25 | $15.2M | $-110.7M | ||
| Q1 25 | $25.0M | $-167.8M | ||
| Q4 24 | $171.2M | $-79.5M | ||
| Q3 24 | $19.1M | $-68.6M | ||
| Q2 24 | $39.4M | $-79.0M |
| Q1 26 | — | — | ||
| Q4 25 | 116.5% | -48.6% | ||
| Q3 25 | 32.8% | -58.0% | ||
| Q2 25 | 13.7% | -66.5% | ||
| Q1 25 | 24.3% | -120.5% | ||
| Q4 24 | 163.5% | -48.3% | ||
| Q3 24 | 18.8% | -49.2% | ||
| Q2 24 | 39.7% | -53.7% |
| Q1 26 | — | — | ||
| Q4 25 | 3.4% | 0.5% | ||
| Q3 25 | 0.3% | 0.8% | ||
| Q2 25 | 1.0% | 1.5% | ||
| Q1 25 | 2.0% | 1.0% | ||
| Q4 24 | 3.8% | 0.1% | ||
| Q3 24 | 0.6% | 1.2% | ||
| Q2 24 | 0.7% | 1.4% |
| Q1 26 | — | — | ||
| Q4 25 | 4.06× | — | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 0.54× | — | ||
| Q1 25 | 0.96× | — | ||
| Q4 24 | 5.78× | — | ||
| Q3 24 | 0.65× | — | ||
| Q2 24 | 1.35× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BY
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
